You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 1,356.00p
Change Today:
-10.00p
Market Cap:
1,167.36m
Sector:
Pharmaceuticals & Biotechnology

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

By Iain Gilbert

Date: Tuesday 19 Oct 2021

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.
Oxford Biomedica stated that under the terms of the option and license agreement, Boehringer Ingelheim will pay it an option exercise fee of 3.5m, while also being entitled to further development, regulatory and sales milestones of up to an additional 27.5m and a "tiered low single-digit royalty" on net sales of the cystic fibrosis gene therapy product.

Boehringer's move follows on from the striking of a development and supply agreement between the pair in April, which covered the clinical manufacture of various types of viral vector-based products.

Elsewhere, the German pharmaceutical group also exercised an option to license intellectual property and know-how from IP Group and the UK Cystic Fibrosis Gene Therapy Consortium in relation to the same lentiviral vector-based product candidate.

As of 0915 BST, Oxford Biomedica shares had inched ahead 0.33% to 1,494.92p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 1,356.00p
Change Today -10.00p
52 Week High 1,634.00p
52 Week Low 820.00p
Volume 72,160
Shares Issued 86.09m
Market Cap 1,167.36m
Beta 0.71

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 5
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 26-Nov-2021

Time Volume / Share Price
16:49 1,580 @ 1,356.00p
16:35 14,659 @ 1,356.00p
16:29 40 @ 1,358.00p
16:29 57 @ 1,354.00p
16:29 100 @ 1,354.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter